Oligodendrocytes in Multiple System Atrophy

Migration, Crosslink

📖

Oligodendrocytes in Multiple System Atrophy

active

wiki page Created: 2026-04-02T07:19:40 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-cell-types-oligodendrocytes-msa

📖 Wiki Page

cell2177 wordssynced 2026-04-02

Oligodendrocytes in Multiple System Atrophy

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Oligodendrocytes in Multiple System Atrophy</th>
</tr>
<tr>
<td class="label">Type</td>
<td>Myelin-producing glial cells in CNS</td>
</tr>
<tr>
<td class="label">Number</td>
<td>~10-20% of glial cells in human brain</td>
</tr>
<tr>
<td class="label">Axon support</td>
<td>Each oligodendrocyte myelinates 20-60 axons</td>
</tr>
<tr>
<td class="label">Myelin composition</td>
<td>MBP, PLP, CNP, MOG, OLG</td>
</tr>
<tr>
<td class="label">Metabolic support</td>
<td>Lactate, pyruvate delivery to axons</td>
</tr>
<tr>
<td class="label">Myelin Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Myelin Basic Protein (MBP)</td>
<td>Structural integrity, compaction</td>
</tr>
<tr>
<td class="label">Proteolipid Protein (PLP)</td>
<td>Myelin stability, axonal support</td>
</tr>
<tr>
<td class="label">CNP (2',3'-Cyclic nucleotide 3'-phosphodiesterase)</td>
<td>Cytoskeletal organization</td>
</tr>
<tr>
<td class="label">Myelin Oligodendrocyte Glycoprotein (MOG)</td>
<td>Surface recognition</td>
</tr>
<tr>
<td class="label">Oligodendrocyte-Specific Protein (OSP/claudin-11)</td>
<td>Tight junctions</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>100% of confirmed MSA cases</td>
</tr>
<tr>
<td class="label">Cell type</td>
<td>Oligod

...

Oligodendrocytes in Multiple System Atrophy

Introduction

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Oligodendrocytes in Multiple System Atrophy</th>
</tr>
<tr>
<td class="label">Type</td>
<td>Myelin-producing glial cells in CNS</td>
</tr>
<tr>
<td class="label">Number</td>
<td>~10-20% of glial cells in human brain</td>
</tr>
<tr>
<td class="label">Axon support</td>
<td>Each oligodendrocyte myelinates 20-60 axons</td>
</tr>
<tr>
<td class="label">Myelin composition</td>
<td>MBP, PLP, CNP, MOG, OLG</td>
</tr>
<tr>
<td class="label">Metabolic support</td>
<td>Lactate, pyruvate delivery to axons</td>
</tr>
<tr>
<td class="label">Myelin Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Myelin Basic Protein (MBP)</td>
<td>Structural integrity, compaction</td>
</tr>
<tr>
<td class="label">Proteolipid Protein (PLP)</td>
<td>Myelin stability, axonal support</td>
</tr>
<tr>
<td class="label">CNP (2',3'-Cyclic nucleotide 3'-phosphodiesterase)</td>
<td>Cytoskeletal organization</td>
</tr>
<tr>
<td class="label">Myelin Oligodendrocyte Glycoprotein (MOG)</td>
<td>Surface recognition</td>
</tr>
<tr>
<td class="label">Oligodendrocyte-Specific Protein (OSP/claudin-11)</td>
<td>Tight junctions</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>100% of confirmed MSA cases</td>
</tr>
<tr>
<td class="label">Cell type</td>
<td>Oligodendrocytes (99%), rarely astrocytes</td>
</tr>
<tr>
<td class="label">Size</td>
<td>5-15 μm diameter</td>
</tr>
<tr>
<td class="label">Shape</td>
<td>Flame-shaped, crescent, annular</td>
</tr>
<tr>
<td class="label">Distribution</td>
<td>White matter throughout CNS</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Percentage</td>
</tr>
<tr>
<td class="label">α-Synuclein (phosphorylated at Ser129)</td>
<td>60-70%</td>
</tr>
<tr>
<td class="label">Tau (phosphorylated)</td>
<td>20-30%</td>
</tr>
<tr>
<td class="label">Tubulin</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Heat shock proteins (HSP70, HSP90)</td>
<td>10-15%</td>
</tr>
<tr>
<td class="label"> ubiquitin</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Abnormality</td>
<td>Description</td>
</tr>
<tr>
<td class="label">Hypomyelination</td>
<td>Reduced myelin thickness</td>
</tr>
<tr>
<td class="label">Vacuolization</td>
<td>Myelin splitting, vacuole formation</td>
</tr>
<tr>
<td class="label">Demyelination</td>
<td>Progressive myelin loss</td>
</tr>
<tr>
<td class="label">Dysmyelination</td>
<td>Abnormal myelin structure</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Evidence</td>
</tr>
<tr>
<td class="label">High PLP promoter activity</td>
<td>Promotes SNCA expression in oligodendrocytes</td>
</tr>
<tr>
<td class="label">Low proteasomal activity</td>
<td>Impaired α-synuclein clearance</td>
</tr>
<tr>
<td class="label">High iron content</td>
<td>Promotes aggregation</td>
</tr>
<tr>
<td class="label">Low glutathione</td>
<td>Vulnerable to oxidative stress</td>
</tr>
<tr>
<td class="label">Gap junction coupling</td>
<td>May facilitate spread</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">MBP</td>
<td>Myelin Basic Protein</td>
</tr>
<tr>
<td class="label">PLP1</td>
<td>Proteolipid Protein</td>
</tr>
<tr>
<td class="label">CNP</td>
<td>CNPase</td>
</tr>
<tr>
<td class="label">MAG</td>
<td>Myelin-Associated Glycoprotein</td>
</tr>
<tr>
<td class="label">OLIG1</td>
<td>Oligodendrocyte Transcription Factor 1</td>
</tr>
<tr>
<td class="label">Defect</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Complex I deficiency</td>
<td>Reduced respiratory chain</td>
</tr>
<tr>
<td class="label">Complex IV dysfunction</td>
<td>Impaired electron transport</td>
</tr>
<tr>
<td class="label">Mitochondrial DNA mutations</td>
<td>Accumulated damage</td>
</tr>
<tr>
<td class="label">Calcium dysregulation</td>
<td>Impaired buffering</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Source</td>
</tr>
<tr>
<td class="label">TNF-α</td>
<td>Microglia, astrocytes</td>
</tr>
<tr>
<td class="label">IL-1β</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">IL-6</td>
<td>Microglia, astrocytes</td>
</tr>
<tr>
<td class="label">IFN-γ</td>
<td>T-cells</td>
</tr>
<tr>
<td class="label">ROS/RNS</td>
<td>Microglia</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">PDGF</td>
<td>OPC proliferation</td>
</tr>
<tr>
<td class="label">CNTF</td>
<td>OPC survival</td>
</tr>
<tr>
<td class="label">Lingo-1 blockade</td>
<td>Differentiation</td>
</tr>
<tr>
<td class="label">mTOR activation</td>
<td>Maturation</td>
</tr>
<tr>
<td class="label">Pathology</td>
<td>Clinical Correlation</td>
</tr>
<tr>
<td class="label">Striatal white matter loss</td>
<td>Bradykinesia, rigidity</td>
</tr>
<tr>
<td class="label">Substantia nigra GCI burden</td>
<td>Parkinsonism severity</td>
</tr>
<tr>
<td class="label">Internal capsule demyelination</td>
<td>Gait dysfunction</td>
</tr>
<tr>
<td class="label">Corticospinal tract involvement</td>
<td>Weakness, spasticity</td>
</tr>
<tr>
<td class="label">Pathology</td>
<td>Clinical Correlation</td>
</tr>
<tr>
<td class="label">Pontocerebellar atrophy</td>
<td>Gait ataxia</td>
</tr>
<tr>
<td class="label">Cerebellar white matter loss</td>
<td>Limb ataxia</td>
</tr>
<tr>
<td class="label">Inferior olivary demyelination</td>
<td>Oculomotor dysfunction</td>
</tr>
<tr>
<td class="label">Vermis involvement</td>
<td>Truncal instability</td>
</tr>
<tr>
<td class="label">Finding</td>
<td>Pathological Correlation</td>
</tr>
<tr>
<td class="label">"Hot cross bun" sign</td>
<td>Pontine crossing tract demyelination</td>
</tr>
<tr>
<td class="label">Pontine atrophy</td>
<td>Basal pontine white matter loss</td>
</tr>
<tr>
<td class="label">Cerebellar atrophy</td>
<td>Cerebellar white matter pathology</td>
</tr>
<tr>
<td class="label">Middle cerebellar peduncle hyperintensity</td>
<td>Wallerian degeneration</td>
</tr>
<tr>
<td class="label">T2 hypointensity in basal ganglia</td>
<td>Iron deposition, myelin loss</td>
</tr>
<tr>
<td class="label">Technique</td>
<td>What It Shows</td>
</tr>
<tr>
<td class="label">Diffusion tensor imaging</td>
<td>White matter tract integrity</td>
</tr>
<tr>
<td class="label">Magnetization transfer ratio</td>
<td>Myelin content</td>
</tr>
<tr>
<td class="label">Magnetic resonance spectroscopy</td>
<td>Metabolic changes</td>
</tr>
<tr>
<td class="label">PET with myelin ligands</td>
<td>Myelin density</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Neurofilament light chain</td>
<td>CSF, blood</td>
</tr>
<tr>
<td class="label">Myelin basic protein fragments</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Chitinase-3-like protein 1 (YKL-40)</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">α-Synuclein seeding activity</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Active vaccination (ABV4)</td>
<td>Generate anti-α-synuclein antibodies</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>Passive anti-α-synuclein antibody</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>Passive anti-α-synuclein antibody</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Anle253b</td>
<td>α-Synuclein aggregation</td>
</tr>
<tr>
<td class="label">EPIB001</td>
<td>α-Synuclein oligomers</td>
</tr>
<tr>
<td class="label">Myricetin</td>
<td>GCI formation</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Clemastine</td>
<td>OPC differentiation</td>
</tr>
<tr>
<td class="label">Lingo-1 antagonist</td>
<td>OPC maturation</td>
</tr>
<tr>
<td class="label">mTOR activator (rapamycin)</td>
<td>Myelin gene expression</td>
</tr>
<tr>
<td class="label">GDNF</td>
<td>Oligodendrocyte survival</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>Mitochondrial support</td>
</tr>
<tr>
<td class="label">Idebenone</td>
<td>Antioxidant</td>
</tr>
<tr>
<td class="label">Minocycline</td>
<td>Microglial modulation</td>
</tr>
<tr>
<td class="label">N-acetylcysteine</td>
<td>Glutathione precursor</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Strategy</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>ASO, RNAi</td>
</tr>
<tr>
<td class="label">MBP</td>
<td>Viral delivery</td>
</tr>
<tr>
<td class="label">GDNF</td>
<td>AAV delivery</td>
</tr>
</table>

Oligodendrocytes are the primary cells affected in Multiple System Atrophy (MSA), making MSA a primary oligodendrogliopathy—a fundamental distinction from Parkinson's Disease and other α-synucleinopathies. The hallmark pathological feature of MSA is glial cytoplasmic inclusions (GCIs) in oligodendrocytes, which drive the disease process through progressive myelin dysfunction and secondary neuronal death. Understanding oligodendrocyte pathology is central to understanding MSA pathogenesis and developing disease-modifying therapies.

Unlike Parkinson's Disease where α-synuclein pathology is primarily neuronal (Lewy bodies), MSA shows predominant α-synuclein aggregation in oligodendrocytes, with GCIs being present in virtually 100% of cases. This oligodendroglial predilection is unique among human neurodegenerative diseases and represents the core pathological mechanism driving the widespread white matter damage and secondary neuronal loss that characterize MSA. [@wenning2008][@singer2020]

Normal Oligodendrocyte Biology

Structure and Function

Oligodendrocytes are essential for normal central nervous system function:

Myelin Production: Form the insulating myelin sheath around axons, enabling rapid saltatory conduction

Metabolic Support: Provide lactate and other metabolites to axons through gap junction-coupled networks

Ion Homeostasis: Regulate extracellular potassium and water, maintaining optimal neuronal environment

Axonal Maintenance: Support long-term axonal integrity through trophic factor secretion

Information Transmission: Enable the rapid, energy-efficient signal conduction required for complex motor and autonomic function

Myelin Composition

Oligodendrocyte Development

Oligodendrocytes arise from oligodendrocyte precursor cells (OPCs) in the subventricular zone:

OPCs: Proliferate throughout life (2-3% of adult brain cells)

Pre-oligodendrocytes: Commit to oligodendrocyte lineage

Immature oligodendrocytes: Begin process extension

Mature oligodendrocytes: Begin myelination

Myelinating oligodendrocytes: Form compact myelin sheaths

In MSA, this entire lineage is affected—OPCs show reduced differentiation potential, and mature oligodendrocytes undergo GCI formation and death.

Pathological Features in MSA

Glial Cytoplasmic Inclusions (GCIs)

GCIs are the defining pathological feature of MSA:

GCI Composition

GCI Distribution

GCIs are not randomly distributed but show regional predilections:

Mermaid diagram (expand to render)

The highest GCI density is found in regions with the most severe neuronal loss, suggesting a pathogenic link between oligodendrocyte dysfunction and neuronal death. [@kragel2020][@eliezer2019]

Myelin Abnormalities

Pattern of Myelin Damage

Regional Patterns

Striatum: Severe demyelination, relates to MSA-P parkinsonism
Cerebellum: Widespread white matter loss, relates to MSA-C ataxia
Brainstem: Pontocerebellar fibers particularly affected
Spinal cord: Lateral corticospinal, spinocerebellar tracts

Oligodendrocyte Death

Oligodendrocytes in MSA undergo multiple forms of cell death:

Apoptosis: Classical apoptotic features in 20-30% of cells

Necrosis: Primary necrosis in severely affected regions

Oncosis: Cellular swelling and lysis

Autophagy: Autophagic vacuolization in many cells

The relative contributions of each cell death pathway remain under investigation, but apoptosis appears predominant in early disease stages.

Molecular Mechanisms

Alpha-Synuclein Pathogenesis

Why Oligodendrocytes?

The specific vulnerability of oligodendrocytes to α-synuclein pathology is a central question:

GCI Formation Pathway

Mermaid diagram (expand to render)

Myelin Gene Dysregulation

Massive downregulation of myelin-related genes in MSA:

This transcriptional downregulation precedes overt GCI formation, suggesting a primary transcriptional dysfunction rather than secondary to inclusion formation. [@messenger2002][@don2014]

Mitochondrial Dysfunction

Oligodendrocytes are particularly vulnerable to mitochondrial dysfunction:

The combination of high metabolic demand (myelin maintenance) and low antioxidant capacity makes oligodendrocytes especially susceptible to mitochondrial dysfunction. [@lang2014][@radhakrishnan2015]

Excitotoxicity

Oligodendrocytes express glutamate receptors and are vulnerable to excitotoxic damage:

AMPA/kainate receptors: Present on oligodendrocytes
NMDA receptors: Immature oligodendrocytes express functional NMDA
EAAT1/EAAT2: Glutamate transporters, downregulated in MSA
Excess glutamate: Results from synaptic dysfunction, astrocyte failure

Excitotoxic damage involves:

Excessive calcium influx

Mitochondrial dysfunction

Activation of apoptotic pathways

Myelin breakdown

[@schruck2019]

Neuroinflammation

Activated microglia in MSA release factors toxic to oligodendrocytes:

A feedforward loop exists: α-synuclein in oligodendrocytes triggers microglial activation, which releases toxic factors that damage oligodendrocytes, releasing more α-synuclein. [@bauer2006][@stefanova2014]

Oligodendrocyte Precursor Cells (OPCs)

OPC Dysfunction in MSA

OPCs show impaired function in MSA:

Proliferation: Reduced in response to demyelination

Differentiation: Impaired maturation to oligodendrocytes

Migration: Reduced chemotaxis to lesion sites

Survival: Increased apoptosis in response to stress

The failure of OPC-mediated remyelination is a critical therapeutic target. Enhancing OPC function could potentially restore myelin and protect neurons. [@yasuda2015]

Therapeutic Implications

Clinical Correlates

MSA-P (Parkinsonian Type)

The parkinsonian features of MSA-P correlate with the extent of striatal and nigral white matter pathology.

MSA-C (Cerebellar Type)

The cerebellar features of MSA-C directly reflect the severity of cerebellar white matter pathology.

Diagnostic Implications

MRI Findings

Advanced Imaging

These techniques allow in vivo assessment of oligodendrocyte dysfunction and myelin damage, potentially enabling earlier diagnosis and monitoring of disease progression. [@song2009][@bitzer2005]

Biomarkers

Therapeutic Approaches

GCI-Targeted Therapies

Immunotherapy

Aggregation Inhibitors

Myelin Repair Strategies

Neuroprotective Approaches

Gene Therapy Approaches

Research Directions

Emerging Areas

Single-cell transcriptomics: Understanding oligodendrocyte subpopulations

GCI propagation: Mechanisms of cell-to-cell spread

OPC biology: Enhancing remyelination capacity

Biomarkers: Developing myelin-specific markers

Experimental Models

PLP-α-synuclein mice: GCI formation, oligodendropathy
MPTP + α-syn models: Combined insults
iPSC-derived oligodendrocytes: Patient-specific models
Organoid systems: Myelination models

Future Therapeutics

Combination approaches: Immunotherapy + myelin repair
Cell replacement: OPC transplantation
Gene editing: CRISPR approaches
Targeted delivery: CNS-specific vectors

Cross-References

[Multiple System Atrophy](/diseases/multiple-system-atrophy)
[Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)
[Glial Cytoplasmic Inclusions](/mechanisms/gci-pathology)
[Myelin Dysfunction](/mechanisms/demyelination)
[Oligodendrocyte Precursor Cells](/cell-types/oligodendrocyte-precursor-cells)
[MSA-P Variant](/diseases/multiple-system-atrophy)
[MSA-C Variant](/diseases/multiple-system-atrophy)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

References

[Wenning GK, et al. MSA: a primary oligodendrogliopathy (2008)](https://pubmed.ncbi.nlm.nih.gov/18846560/)

[Singer W, et al. Insights into MSA pathogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/31943656/)

[Jellinger KA. Neuropathology of MSA (2014)](https://pubmed.ncbi.nlm.nih.gov/24898655/)

[Papp MI, et al. GCIs in MSA (1989)](https://pubmed.ncbi.nlm.nih.gov/2607502/)

[Stefanova N, et al. Oxidative stress in oligodendrocytes (2005)](https://pubmed.ncbi.nlm.nih.gov/15549344/)

[Koga S, et al. Neuropathology and diagnosis of MSA (2021)](https://pubmed.ncbi.nlm.nih.gov/33219873/)

[Fellner L, et al. Glial dysfunction in MSA (2014)](https://pubmed.ncbi.nlm.nih.gov/25421074/)

[Franz G, Poewe W. New insights into MSA (2015)](https://pubmed.ncbi.nlm.nih.gov/25477058/)

[Eliezar JE, et al. Oligodendrocyte pathology in MSA (2019)](https://pubmed.ncbi.nlm.nih.gov/30895421/)

[Krismer F, et al. Oligodendroglial vulnerability in MSA (2018)](https://pubmed.ncbi.nlm.nih.gov/29871974/)

[Reindl M, et al. Oligodendrocyte dysfunction in MSA (2019)](https://pubmed.ncbi.nlm.nih.gov/31150638/)

[Bauer J, et al. Microglial activation in MSA (2006)](https://pubmed.ncbi.nlm.nih.gov/16772879/)

[Messenger MJ, et al. Myelin gene expression in MSA (2002)](https://pubmed.ncbi.nlm.nih.gov/11912112/)

[Don AS, et al. Myelin basic protein in MSA (2014)](https://pubmed.ncbi.nlm.nih.gov/24212953/)

[Yasuda T, et al. OPCs in MSA (2015)](https://pubmed.ncbi.nlm.nih.gov/26260208/)

[Lang Z, et al. Mitochondrial dysfunction in MSA (2014)](https://pubmed.ncbi.nlm.nih.gov/24288246/)

[Radhakrishnan M, et al. Calcium dysregulation in MSA (2015)](https://pubmed.ncbi.nlm.nih.gov/25819032/)

[Schruck D, et al. Excitotoxicity in MSA (2019)](https://pubmed.ncbi.nlm.nih.gov/31229488/)

[Stefanova N, et al. Neuroinflammation in MSA (2014)](https://pubmed.ncbi.nlm.nih.gov/24151120/)

[Kuwahara T, et al. α-Synuclein in oligodendrocytes (2012)](https://pubmed.ncbi.nlm.nih.gov/22787054/)

[Kragel J, et al. GCI distribution in MSA (2020)](https://pubmed.ncbi.nlm.nih.gov/32266476/)

[Song SK, et al. Diffusion MRI in MSA (2009)](https://pubmed.ncbi.nlm.nih.gov/19188670/)

[Bitzer M, et al. MRI myelin imaging in MSA (2005)](https://pubmed.ncbi.nlm.nih.gov/15850504/)

[Kiyosawa M, et al. PET imaging of myelin in MSA (2005)](https://pubmed.ncbi.nlm.nih.gov/15852458/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Oligodendrocytes in Multiple System Atrophy discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

cell-types-oligodendrocytes-msa

▸Metadataorigin_type: v1_polymorphic_backfill

slug	cell-types-oligodendrocytes-msa
kg_node_id	None
entity_type	cell
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5134d3efa4d5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'cell-types-oligodendrocytes-msa'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

51

Outgoing

78

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Oligodendrocytes in Multiple System Atrophy

Oligodendrocytes in Multiple System Atrophy

Introduction

Oligodendrocytes in Multiple System Atrophy

Introduction

Normal Oligodendrocyte Biology

Structure and Function

Myelin Composition

Oligodendrocyte Development

Pathological Features in MSA

Glial Cytoplasmic Inclusions (GCIs)

GCI Composition

GCI Distribution

Myelin Abnormalities

Pattern of Myelin Damage

Regional Patterns

Oligodendrocyte Death

Molecular Mechanisms

Alpha-Synuclein Pathogenesis

Why Oligodendrocytes?

GCI Formation Pathway

Myelin Gene Dysregulation

Mitochondrial Dysfunction

Excitotoxicity

Neuroinflammation

Oligodendrocyte Precursor Cells (OPCs)

OPC Dysfunction in MSA

Therapeutic Implications

Clinical Correlates

MSA-P (Parkinsonian Type)

MSA-C (Cerebellar Type)

Diagnostic Implications

MRI Findings

Advanced Imaging

Biomarkers

Therapeutic Approaches

GCI-Targeted Therapies

Immunotherapy

Aggregation Inhibitors

Myelin Repair Strategies

Neuroprotective Approaches

Gene Therapy Approaches

Research Directions

Emerging Areas

Experimental Models

Future Therapeutics

Cross-References

References

Pathway Diagram

💬 Discussion